Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius Buys 10,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the transaction, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Tuesday, March 11th, Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00.

Elanco Animal Health Trading Down 6.8 %

Shares of Elanco Animal Health stock opened at $10.07 on Wednesday. The firm’s 50 day moving average is $11.56 and its 200 day moving average is $12.83. The firm has a market capitalization of $4.98 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 1 year low of $10.03 and a 1 year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently modified their holdings of the company. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $35,000. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter valued at $29,000. Farther Finance Advisors LLC boosted its holdings in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after acquiring an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after acquiring an additional 1,601 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ELAN. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Piper Sandler cut their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.